David A. Ehrmann to Male
This is a "connection" page, showing publications David A. Ehrmann has written about Male.
Connection Strength
0.193
-
Nonalcoholic fatty liver disease and obstructive sleep apnea in women with polycystic ovary syndrome. Fertil Steril. 2022 05; 117(5):897-911.
Score: 0.044
-
Longitudinal relationship of diabetes-related distress and depressive symptoms: analysing incidence and persistence. Diabet Med. 2015 Oct; 32(10):1264-71.
Score: 0.028
-
Insulin secretory responses to rising and falling glucose concentrations are delayed in subjects with impaired glucose tolerance. Diabetologia. 2002 Apr; 45(4):509-17.
Score: 0.011
-
Obstructive Sleep Apnea, Glucose Tolerance, and ß-Cell Function in Adults With Prediabetes or Untreated Type 2 Diabetes in the Restoring Insulin Secretion (RISE) Study. Diabetes Care. 2021 04; 44(4):993-1001.
Score: 0.010
-
Withdrawal of medications leads to worsening of OGTT parameters in youth with impaired glucose tolerance or recently-diagnosed type 2 diabetes. Pediatr Diabetes. 2020 12; 21(8):1437-1446.
Score: 0.010
-
The association of sleep disturbances with glycemia and obesity in youth at risk for or with recently diagnosed type 2 diabetes. Pediatr Diabetes. 2019 12; 20(8):1056-1063.
Score: 0.009
-
Association of Habitual Daily Physical Activity With Glucose Tolerance and ß-Cell Function in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes From the Restoring Insulin Secretion (RISE) Study. Diabetes Care. 2019 08; 42(8):1521-1529.
Score: 0.009
-
Association of Self-Reported Sleep and Circadian Measures With Glycemia in Adults With Prediabetes or Recently Diagnosed Untreated Type 2 Diabetes. Diabetes Care. 2019 07; 42(7):1326-1332.
Score: 0.009
-
The effect of an education programme (MEDIAS 2 BSC) of non-intensive insulin treatment regimens for people with Type 2 diabetes: a randomized, multi-centre trial. Diabet Med. 2017 08; 34(8):1084-1091.
Score: 0.008
-
Lifestyle and Metformin Ameliorate Insulin Sensitivity Independently of the Genetic Burden of Established Insulin Resistance Variants in Diabetes Prevention Program Participants. Diabetes. 2016 Feb; 65(2):520-6.
Score: 0.007
-
Impaired insulin signaling in human adipocytes after experimental sleep restriction: a randomized, crossover study. Ann Intern Med. 2012 Oct 16; 157(8):549-57.
Score: 0.006
-
Potential diagnostic utility of intermittent administration of short-acting gonadotropin-releasing hormone agonist in gonadotropin deficiency. Fertil Steril. 2010 Dec; 94(7):2697-702.
Score: 0.005
-
Use of nafarelin for testing pituitary-ovarian function. J Reprod Med. 1989 Dec; 34(12 Suppl):1044-50.
Score: 0.005
-
A new test of combined pituitary-testicular function using the gonadotropin-releasing hormone agonist nafarelin in the differentiation of gonadotropin deficiency from delayed puberty: pilot studies. J Clin Endocrinol Metab. 1989 Nov; 69(5):963-7.
Score: 0.005
-
Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome. N Engl J Med. 1989 Mar 02; 320(9):559-65.
Score: 0.004
-
Limitations to the use of a sensitive assay for serum thyrotropin in the assessment of thyroid status. Arch Intern Med. 1989 Feb; 149(2):369-72.
Score: 0.004
-
Slow-wave sleep and the risk of type 2 diabetes in humans. Proc Natl Acad Sci U S A. 2008 Jan 22; 105(3):1044-9.
Score: 0.004
-
Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes. 2005 Apr; 54(4):1150-6.
Score: 0.003
-
Quantitative indexes of beta-cell function during graded up&down glucose infusion from C-peptide minimal models. Am J Physiol Endocrinol Metab. 2001 Jan; 280(1):E2-10.
Score: 0.003
-
Transmission ratio distortion at the INS-IGF2 VNTR. Nat Genet. 1999 Aug; 22(4):324-5.
Score: 0.002
-
Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest. 1997 Aug 01; 100(3):530-7.
Score: 0.002
-
Acute hormonal responses to the gonadotropin releasing hormone agonist leuprolide: dose-response studies and comparison to nafarelin--a clinical research center study. J Clin Endocrinol Metab. 1996 Sep; 81(9):3408-11.
Score: 0.002
-
The GENNID Study. A resource for mapping the genes that cause NIDDM. Diabetes Care. 1996 Aug; 19(8):864-72.
Score: 0.002
-
Maturation of gonadotropin and sex steroid responses to gonadotropin-releasing hormone agonist in males. J Clin Endocrinol Metab. 1993 Feb; 76(2):362-6.
Score: 0.001
-
Adrenal localization in the adrenocorticotropic hormone-independent Cushing syndrome. Ann Intern Med. 1988 Oct 01; 109(7):547-53.
Score: 0.001